Temporary omission of oral anticoagulation in atrial fibrillation patients undergoing percutaneous coronary intervention: rationale and design of the WOEST-3 randomised trial.
Humans
Atrial Fibrillation
/ complications
Percutaneous Coronary Intervention
/ adverse effects
Anticoagulants
/ administration & dosage
Administration, Oral
Platelet Aggregation Inhibitors
/ administration & dosage
Hemorrhage
/ chemically induced
Aspirin
/ therapeutic use
Dual Anti-Platelet Therapy
/ methods
Male
Female
Aged
Purinergic P2Y Receptor Antagonists
/ administration & dosage
Treatment Outcome
Middle Aged
Journal
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
ISSN: 1969-6213
Titre abrégé: EuroIntervention
Pays: France
ID NLM: 101251040
Informations de publication
Date de publication:
15 Jul 2024
15 Jul 2024
Historique:
medline:
15
7
2024
pubmed:
15
7
2024
entrez:
15
7
2024
Statut:
epublish
Résumé
The optimal antithrombotic management of atrial fibrillation (AF) patients who require oral anticoagulation (OAC) undergoing percutaneous coronary intervention (PCI) remains unclear. Current guidelines recommend dual antithrombotic therapy (DAT; OAC plus P2Y
Identifiants
pubmed: 39007830
pii: EIJ-D-24-00100
doi: 10.4244/EIJ-D-24-00100
pii:
doi:
Substances chimiques
Anticoagulants
0
Platelet Aggregation Inhibitors
0
Aspirin
R16CO5Y76E
Purinergic P2Y Receptor Antagonists
0
Banques de données
ClinicalTrials.gov
['NCT04436978']
Types de publication
Journal Article
Randomized Controlled Trial
Clinical Trial Protocol
Langues
eng
Sous-ensembles de citation
IM